The 2017-2018 influenza season in Bucharest, Romania: epidemiology and characteristics of hospital admissions for influenza-like illness.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
12 Nov 2019
Historique:
received: 14 05 2019
accepted: 31 10 2019
entrez: 14 11 2019
pubmed: 14 11 2019
medline: 18 12 2019
Statut: epublish

Résumé

Seasonal influenza causes a considerable burden to healthcare services every year. To better measure the impact of severe influenza cases in Romania, we analyzed active surveillance data collected during the 2017-2018 season from patients admitted for influenza-like illness (ILI) at a tertiary care hospital in Bucharest. Patients admitted for acute ILI were included if they were resident in the Bucharest-Ilfov region, had been hospitalized for at least 24 h, and had onset of symptoms within 7 days before admission. Patient demographics, healthcare use, vaccination status, and outcome data were collected by questionnaire or by searching clinical records. Respiratory swabs were also obtained from each patient to confirm influenza A (A/H1 and A/H3 subtypes) or influenza B (Yamagata and Victoria lineages) infection by real-time reverse-transcription polymerase chain reaction assay. The study included 502 patients, many (45.2%) of whom were aged < 5 years. Overall, 108 patients (21.5%) had one or more comorbidities. Seventeen adults aged 18-64 years (3.4%) had been vaccinated against influenza. Patients were hospitalized for a median of 5 days and most (90.4%) were prescribed antiviral treatment. More than one-half of the patients (n = 259, 51.6%) were positive for influenza. Most influenza cases were caused by B viruses (172/259, 66.4%), which were mostly of the B/Yamagata lineage (85 of 94 characterized, 90.4%). Most of the subtyped A viruses were A/H1 (59/74, 79.7%). A/H1 viruses were frequently detected in influenza-positive admissions throughout the 2017-2018 season, whereas the predominant B/Yamagata viruses were detected around the middle of the season, with a peak in cases at week 7 of 2018. Eleven patients were admitted to an intensive care unit; of these, one patient with confirmed B/Yamagata infection died. These results show that seasonal influenza results in considerable hospitalization in Bucharest-Ilfov, Romania and suggest vaccine coverage should be extended, especially to the youngest age groups. The data from this study should help inform and optimize national influenza healthcare policies.

Sections du résumé

BACKGROUND BACKGROUND
Seasonal influenza causes a considerable burden to healthcare services every year. To better measure the impact of severe influenza cases in Romania, we analyzed active surveillance data collected during the 2017-2018 season from patients admitted for influenza-like illness (ILI) at a tertiary care hospital in Bucharest.
METHODS METHODS
Patients admitted for acute ILI were included if they were resident in the Bucharest-Ilfov region, had been hospitalized for at least 24 h, and had onset of symptoms within 7 days before admission. Patient demographics, healthcare use, vaccination status, and outcome data were collected by questionnaire or by searching clinical records. Respiratory swabs were also obtained from each patient to confirm influenza A (A/H1 and A/H3 subtypes) or influenza B (Yamagata and Victoria lineages) infection by real-time reverse-transcription polymerase chain reaction assay.
RESULTS RESULTS
The study included 502 patients, many (45.2%) of whom were aged < 5 years. Overall, 108 patients (21.5%) had one or more comorbidities. Seventeen adults aged 18-64 years (3.4%) had been vaccinated against influenza. Patients were hospitalized for a median of 5 days and most (90.4%) were prescribed antiviral treatment. More than one-half of the patients (n = 259, 51.6%) were positive for influenza. Most influenza cases were caused by B viruses (172/259, 66.4%), which were mostly of the B/Yamagata lineage (85 of 94 characterized, 90.4%). Most of the subtyped A viruses were A/H1 (59/74, 79.7%). A/H1 viruses were frequently detected in influenza-positive admissions throughout the 2017-2018 season, whereas the predominant B/Yamagata viruses were detected around the middle of the season, with a peak in cases at week 7 of 2018. Eleven patients were admitted to an intensive care unit; of these, one patient with confirmed B/Yamagata infection died.
CONCLUSIONS CONCLUSIONS
These results show that seasonal influenza results in considerable hospitalization in Bucharest-Ilfov, Romania and suggest vaccine coverage should be extended, especially to the youngest age groups. The data from this study should help inform and optimize national influenza healthcare policies.

Identifiants

pubmed: 31718578
doi: 10.1186/s12879-019-4613-z
pii: 10.1186/s12879-019-4613-z
pmc: PMC6852761
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

967

Subventions

Organisme : Foundation for Influenza Epidemiology
ID : GIHSN grant 2017/18

Références

Influenza Other Respir Viruses. 2014 Jan;8(1):8-12
pubmed: 24251915
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Hum Vaccin Immunother. 2012 Jan;8(1):81-8
pubmed: 22252006
Hum Vaccin Immunother. 2014;10(2):428-40
pubmed: 24165394
Germs. 2019 Sep 02;9(3):142-147
pubmed: 31646144
Hum Vaccin Immunother. 2018;14(11):2706-2714
pubmed: 29923782
Influenza Other Respir Viruses. 2015 Nov;9(6):277-286
pubmed: 26198771
Euro Surveill. 2018 Mar;23(13):
pubmed: 29616611
Braz J Infect Dis. 2018 Sep - Oct;22(5):377-386
pubmed: 30391275
Influenza Other Respir Viruses. 2018 Jan;12(1):183-192
pubmed: 29144598
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:3-12
pubmed: 26256290

Auteurs

Anca Drăgănescu (A)

Children X Department, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.

Oana Săndulescu (O)

Adults II Department, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania. oana.sandulescu@umfcd.ro.
Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. oana.sandulescu@umfcd.ro.

Dragoș Florea (D)

Molecular Diagnosis Laboratory, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.
Department of Microbiology I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Ovidiu Vlaicu (O)

Molecular Diagnosis Laboratory, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.

Anca Streinu-Cercel (A)

Adults II Department, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.
Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Dan Oțelea (D)

Molecular Diagnosis Laboratory, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.

Monica Luminița Luminos (ML)

Children X Department, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.
Department of Infectious Diseases, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Victoria Aramă (V)

Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Adults III Department, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.

Sorin Abrudan (S)

Medical CEE, Sanofi Pasteur, Bucharest, Romania.

Adrian Streinu-Cercel (A)

Adults II Department, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.
Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Daniela Pițigoi (D)

Compartment for Surveillance and Prevention of Healthcare-associated Infections, National Institute for Infectious Diseases 'Prof. Dr. Matei Balş', Bucharest, Romania.
Department of Epidemiology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH